| human | Q5 |
| P6178 | Dimensions author ID | 01255705374.56 |
| P2798 | Loop ID | 31407 |
| P3835 | Mendeley person ID | miguel-medina15 |
| P496 | ORCID iD | 0000-0002-7016-5340 |
| P3829 | Publons author ID | 2707405 |
| P1053 | ResearcherID | H-5676-2012 |
| P1153 | Scopus author ID | 55559087700 |
| 55701313600 | ||
| 57189580915 |
| P734 | family name | Medina | Q15700013 |
| Medina | Q15700013 | ||
| Medina | Q15700013 | ||
| P735 | given name | Miguel | Q15620295 |
| Miguel | Q15620295 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q46352528 | A delta-catenin signaling pathway leading to dendritic protrusions |
| Q47884036 | A longitudinal FDG-PET study of transgenic mice overexpressing GSK- 3β in the brain |
| Q28391511 | Additional mechanisms conferring genetic susceptibility to Alzheimer's disease |
| Q90351867 | An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration |
| Q52594209 | An Overview on the Clinical Development of Tau-Based Therapeutics. |
| Q46519468 | Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice |
| Q58712518 | Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus |
| Q60287698 | Bioactive prenylated phenyl derivatives derived from marine natural products: novel scaffolds for the design of BACE inhibitors |
| Q37306377 | Clinical Relevance of Specific Cognitive Complaints in Determining Mild Cognitive Impairment from Cognitively Normal States in a Study of Healthy Elderly Controls |
| Q42135408 | Deconstructing GSK-3: The Fine Regulation of Its Activity |
| Q40352789 | Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease |
| Q89052888 | Detecting Circulating MicroRNAs as Biomarkers in Alzheimer's Disease |
| Q40380514 | Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. |
| Q52251559 | Drosophila cathepsin B-like proteinase: a suggested role in yolk degradation. |
| Q48326380 | Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. |
| Q93039889 | Effects of commonly prescribed drugs on cognition and mild cognitive impairment in healthy elderly people |
| Q91443167 | Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment |
| Q48215823 | EuroTau: towing scientists to tau without tautology. |
| Q54453858 | Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. |
| Q24610904 | Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib |
| Q52175951 | Expression of presenilin 1 in nervous system during rat development. |
| Q38306065 | Further understanding of tau phosphorylation: implications for therapy. |
| Q71736203 | Glycogen synthase kinase 3 phosphorylates recombinant human tau protein at serine-262 in the presence of heparin (or tubulin) |
| Q37779109 | Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. |
| Q33294648 | Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. |
| Q28144688 | Hemizygosity of delta-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndrome |
| Q71683393 | Identification of protein kinases that modify specific epitopes |
| Q50470390 | Is tau a prion-like protein? |
| Q112298313 | Long runs of homozygosity are associated with Alzheimer's disease |
| Q60777409 | Longitudinal Assessment of a Transgenic Animal Model of Tauopathy by FDG-PET Imaging |
| Q33251948 | Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases |
| Q38609658 | MicroRNAs in Neurodegenerative Diseases. |
| Q41596913 | Modifications of the 5' untranslated region of foot-and-mouth disease virus after prolonged persistence in cell culture |
| Q37946881 | Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies |
| Q46197592 | NP7 protects from cell death induced by oxidative stress in neuronal and glial midbrain cultures from parkin null mice |
| Q41967267 | Neuronal membrane cholesterol loss enhances amyloid peptide generation |
| Q26750922 | New Features about Tau Function and Dysfunction |
| Q37978196 | New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. |
| Q38149943 | New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. |
| Q38181831 | New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. |
| Q37827537 | Overcoming cell death and tau phosphorylation mediated by PI3K-inhibition: a cell assay to measure neuroprotection. |
| Q37103011 | Potent beta-amyloid modulators. |
| Q41116079 | Presenilin 1 interaction in the brain with a novel member of the Armadillo family |
| Q52163097 | Presenilin affects arm/beta-catenin localization and function in Drosophila. |
| Q41197954 | Protein kinases involved in the phosphorylation of human tau protein in transfected COS-1 cells. |
| Q39111437 | Recent developments in tau-based therapeutics for Alzheimer's disease and related dementsia |
| Q37813731 | Recent developments in tau-based therapeutics for neurodegenerative diseases |
| Q24671491 | RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability |
| Q61812024 | Role of tau N-terminal motif in the secretion of human tau by End Binding proteins |
| Q87976963 | Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro |
| Q40809749 | Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment. |
| Q47743999 | Strong buffering capacity of insect cells. Implications for the baculovirus expression system |
| Q89052886 | Tau Assembly into Filaments |
| Q90398264 | Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized With DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins |
| Q63101708 | The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention? |
| Q53217318 | The in vitro formation of recombinant tau polymers: effect of phosphorylation and glycation. |
| Q34398962 | The need for better AD animal models |
| Q37734856 | The role of extracellular Tau in the spreading of neurofibrillary pathology. |
| Q41327023 | The role of tau phosphorylation in transfected COS-1 cells |
| Q45775389 | The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities |
| Q40429251 | Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation |
| Q47097900 | Toward common mechanisms for risk factors in Alzheimer's syndrome |
| Q34296827 | Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. |
| Q38101982 | Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes |
| Q36999161 | Use of okadaic acid to identify relevant phosphoepitopes in pathology: a focus on neurodegeneration |
| Q44944491 | Wnt-1 expression in PC12 cells induces exon 15 deletion and expression of L-APP. |
| Q49082951 | delta-catenin is a nervous system-specific adherens junction protein which undergoes dynamic relocalization during development |
Search more.